Peptide Health Lab

Repair & recovery

BPC-157

FOR RESEARCH PURPOSES ONLY

Also known as: Body Protection Compound 157, PL 14736, PLD-116

Regulatory status
Research only
Evidence grade
Animal studies only

Last reviewed July 15, 2026 · 18 sources

What BPC-157 is and how it works

BPC-157 is a synthetic chain of fifteen amino acids. It is not a naturally occurring hormone and it is not a fragment of a drug. It is a partial sequence of a larger protein called Body Protection Compound, which was identified in and isolated from human gastric juice.[4] The sequence usually reported in the literature is GEPPPGKPADDAGLV, with a molecular weight of roughly 1,419 daltons.[3]

The property that made the peptide interesting to its original investigators is stability. Most peptides are destroyed quickly in the stomach; BPC-157 is repeatedly described as stable in human gastric juice, which is why so much of the early rodent work used intragastric administration alongside injection routes.[3]

The mechanism most often proposed is not a single receptor. Instead, the primary research group describes a cluster of downstream effects: recruitment of new blood vessels into injured tissue, interaction with the nitric-oxide system, and modulation of several growth-factor pathways involved in repair.[15][8] The most concrete mechanistic finding outside that group comes from vascular work in isolated rat aorta, where BPC-157 produced concentration-dependent, endothelium-dependent vasodilation through a Src–Caveolin-1–endothelial nitric oxide synthase pathway.[14] That is a real, specific, reproducible signalling result. It is also a result obtained in a tissue bath, not in a person. It is worth holding both of those facts at once, because the gap between "we can describe a plausible mechanism" and "we have shown a clinical benefit" is the entire story of this compound.

What the research actually shows

The rodent literature on BPC-157 is genuinely large, and it is largely consistent within itself.

Gut. The original and deepest research area is gastrointestinal protection. Across rat models of gastric, esophageal, duodenal, and intestinal lesions, the peptide is described as cytoprotective, reducing lesion formation and accelerating mucosal healing; its authors frame the work as a modern extension of Robert's cytoprotection paradigm.[5][13]

NSAID-related injury. In rats given indomethacin, aspirin, or diclofenac, BPC-157 at 10 µg/kg or 10 ng/kg intraperitoneally consistently reduced gastric lesions and small-intestinal damage; the same study reported attenuated disease in an adjuvant-arthritis model followed out to a year.[1] Later reviews build a broader argument about counteracting NSAID toxicity from this base.[7]

Tendon and connective tissue. This is the area driving most current interest. Sharp transection of the Achilles tendon from the calcaneus does not heal spontaneously in rats. In that model, daily intraperitoneal BPC-157 improved functional index scores, load to failure, stiffness, and collagen organization, and reduced the healing impairment caused by concurrent corticosteroid.[2] Supporting cell work found that the peptide accelerated fibroblast outgrowth from tendon explants, improved fibroblast survival under oxidative stress, and increased migration and spreading via the FAK–paxillin pathway,[4] and separately that it increased growth-hormone receptor expression in tendon fibroblasts.[9]

Vascular and neurological. Reviews extend the model into angiogenesis and comparisons with standard angiogenic growth factors,[11] and into the central nervous system and a proposed brain–gut axis.[17][10] These are the furthest-reaching claims in the field and rest almost entirely on one group's animal models.

Where the evidence is weak

This is the section that matters most, and it is not a formality.

There is essentially no human evidence. An independent review of the literature and the patent record states the position plainly: despite pleiotropic beneficial effects in preclinical models, BPC-157 has not been approved by the FDA or other global regulators because sufficient clinical studies confirming human benefit do not exist.[18] A review focused specifically on musculoskeletal soft-tissue healing reaches the same conclusion from the sports medicine side.[12]

The one human report is very small and very weak. A retrospective chart review at a single clinic surveyed sixteen patients by telephone about knee pain after intra-articular injection of BPC-157, alone or with thymosin beta-4. Follow-up intervals varied, pain was self-reported from recall, no standardized instrument was used, there was no control group, and no imaging confirmed any structural change. The authors describe it as a small study and call for future work.[16] That is a hypothesis-generating observation, not evidence of efficacy. It is also the strongest human datum this compound has.

A clinical programme existed and did not produce a published positive trial. Review articles repeatedly reference an inflammatory-bowel-disease programme under the designations PL-10, PLD-116, and PL 14736, and describe the peptide as tolerated in that setting.[3][6] What is not available is a completed, peer-reviewed randomized controlled trial establishing efficacy. A development programme that starts and does not finish is information, and the information is not encouraging.

The literature has a concentration problem. A large share of the primary work comes from a single research group in Zagreb, much of it published in a small cluster of journals, frequently as reviews restating overlapping preclinical findings. That does not make the findings wrong. It does mean the field lacks the independent replication that would normally be expected before a compound is taken seriously for human use, and reviews of positive preclinical literature are not a substitute for a trial.

Long-term safety is unknown. The animal studies were designed to detect healing effects over days to weeks, not uncommon or long-latency harms. Nothing in the published record speaks to years of exposure in humans.

Legal and regulatory status

BPC-157 is not approved by the FDA for any indication, and it is not approved by other major regulators.[18] It is not a dietary supplement ingredient and it is not an approved drug; material labeled BPC-157 is distributed for laboratory research use, which is why every mention of it on this site carries research-only framing.

Its status in tested sport is settled, and stricter than some published summaries suggest. The World Anti-Doping Agency names BPC-157 as an example under section S0, non-approved substances. That class covers any pharmacological substance with no current approval by any governmental regulatory health authority for human therapeutic use, and everything in S0 is prohibited at all times, in competition and out of it. BPC-157 was added to that section by name in the 2022 list and is still named there in the list in force for 2026. The review cited above states that the 2022 ban was temporary and that the compound is not currently listed; that parenthetical is wrong, and it is the origin of a claim that circulates widely.[18] The review remains a reasonable survey of the preclinical literature. It should simply not be relied on for anti-doping status. A competing athlete should confirm the current year's list rather than this page, but the answer has not changed direction since 2022.

Historically, the compound did enter formal pharmaceutical development under sponsor designations for inflammatory bowel disease,[3] which is why it sometimes appears in discussion as though it were a shelved drug. It never completed that path to approval.

PHL does not sell peptides, does not tell anyone how to obtain them, and takes no position on how unapproved material reaches anyone. What the regulatory status means for a reader is narrower and more useful: there is no label, no approved manufacturer, no assigned indication, and no regulated quality standard behind anything labeled BPC-157.

Questions to bring to a provider

The productive version of this conversation is not "should I take BPC-157." It is "here is what I am actually trying to fix. What are the options with evidence behind them, and where does an unapproved peptide sit relative to those?" Questions worth raising:

  • What is the actual diagnosis for the tendon, joint, or gut problem in question, and what does the standard-of-care evidence base offer for it?
  • Given that the entire efficacy literature for this compound is animal and cell work, what would have to be true for it to be worth considering at all?[12]
  • Does a personal or family history of malignancy change the calculus, given that the central proposed mechanism is promotion of new blood-vessel growth?[18]
  • Are there interactions to think through with current cardiovascular medications, anticoagulants, or NSAIDs?
  • If competing in a tested sport, what does this year's prohibited list say?
  • What labs, imaging, or functional testing would make it possible to tell whether anything actually changed, rather than relying on how it feels?

A clinician who takes the question seriously and answers "the evidence isn't there yet" is giving a defensible answer, not a dismissive one.

Evidence by claim

Grades describe how strong the evidence is; the line under each grade describes what kind of studies it is. How we grade evidence.

Tendon and ligament healing
Animal studies only animal · in vitro · review

Rat Achilles-detachment work reported functional and biomechanical improvement in tendon-to-bone healing, and cell work found accelerated fibroblast outgrowth, survival under oxidative stress, and migration, along with increased growth-hormone receptor expression in tendon fibroblasts. All of it is animal or cell-culture work; no human trial has tested it.

[2] [4] [9] [12]

Gastrointestinal mucosal protection and ulcer healing
Animal studies only review

This is the compound's original and best-developed research area: rodent models of gastric, esophageal, duodenal, and intestinal lesions in which the peptide is described as cytoprotective and organoprotective across a wide range of injury types.

[5] [13] [3]

NSAID-associated gastrointestinal injury
Animal studies only animal · review

In rats given indomethacin, aspirin, or diclofenac, the peptide reduced the resulting gastric and small-intestinal lesions, and a parallel effect was reported in an adjuvant-arthritis model. Reviews extend the argument to NSAID toxicity more broadly. Rodent data only.

[1] [7]

Angiogenesis and vascular signalling (proposed mechanism)
Animal studies only review · in vitro

The mechanistic account favored by the primary research group is that BPC-157 recruits blood vessels and interacts with the nitric-oxide system; isolated-aorta work identifies a Src–Caveolin-1–eNOS pathway. Mechanism, not outcome. And that mechanism was established outside humans.

[11] [15] [8] [14]

Central nervous system and brain–gut axis effects
Animal studies only review

Reviews describe effects on rodent CNS models and propose a brain–gut axis role. These are the most speculative claims in the literature and rest almost entirely on one group's animal work.

[17] [10]

Joint pain in humans
Anecdotal reports only human observational

The only human report is a retrospective single-clinic chart review in which 16 patients who had received intra-articular injection were surveyed by phone about their knee pain. No control group, no randomization, no imaging follow-up, recalled pain scores. The authors themselves call for future studies.

[16]

Inflammatory bowel disease in humans
Anecdotal reports only review

Review articles reference a clinical programme (PL 14736 / PLD-116) for inflammatory bowel disease and describe it as having been tolerated, but no completed randomized controlled trial establishing efficacy is available in the peer-reviewed literature.

[6] [3]

Clinical efficacy for any indication in humans
Anecdotal reports only review

There is no published, completed randomized controlled trial supporting any human indication. Recent independent review states directly that BPC-157 has not been approved because clinical studies confirming human benefit are absent.

[18] [12]

FOR RESEARCH PURPOSES ONLY

Typical protocol range in the research

  • Rat studies: the dose pair used across most of the published efficacy work, given intraperitoneally, once daily

    10 µg/kg and 10 ng/kg body weight [2] [1]

  • Human retrospective chart review of intra-articular injection for knee pain (16 patients contacted, single-clinic, no control group)

    A single intra-articular injection; the report does not standardize or state a dose per patient [16]

  • Human clinical programme for inflammatory bowel disease (PL 14736 / PLD-116)

    Early-phase formulations described in review as having been evaluated without reported toxicity; no effective human dose is established in the published literature [3] [6]

The rodent range is the only one with a real evidence base behind it, and it is expressed per kilogram of rat body weight in an intraperitoneal model. It does not translate to a human protocol. No published trial establishes a human dose for any indication.

Ranges are what published research reports, not a recommendation. PHL does not prescribe, and nothing here is personalized to you.

Side effects & safety signals

  • No established human safety profile

    Not established · Unknown. This is an absence of data, not a finding of safety. Reviews of the field note that BPC-157 has not been approved by the FDA or other regulators because sufficient clinical study in humans does not exist.

    [18] [12]

  • Low reported toxicity in preclinical work, from a narrow evidence base

    Few adverse effects reported across the published animal literature · Reviews describe a favorable preclinical safety profile with few reported side effects, and individual rodent studies report no toxicity. That literature is dominated by a small number of research groups and was not designed to detect uncommon or long-latency harms.

    [18] [2]

  • Promotion of angiogenesis as the central proposed mechanism

    Consistently reported across the preclinical literature · Not an adverse effect in itself, but the mechanism cuts both ways: what systemic promotion of new blood-vessel growth means for a person with an angiogenesis-dependent condition has never been studied. A personal or family history of malignancy is a reason to raise this with a clinician before considering anything.

    [11] [15]

  • Vascular and nitric-oxide system activity

    Demonstrated in isolated rat aorta and in rodent models · BPC-157 produces concentration-dependent, endothelium-dependent vasodilation in isolated rat aorta via a Src–Caveolin-1–eNOS pathway, and its effects are repeatedly tied to the nitric-oxide system. Interaction with cardiovascular medication or with existing vascular disease is unstudied and is a provider-discussion flag.

    [14] [8]

  • Unverified identity and purity of unapproved material

    Not quantified · With no approved manufacturer, nothing about the composition, concentration, or contaminant profile of material labeled "BPC-157" is regulated or independently guaranteed. This is a category-level risk that sits on top of whatever the molecule itself does.

    [18]

Published lists are never exhaustive, so report anything unexpected to a licensed provider.

Storage, handling & reconstitution

Lyophilized storage
Lyophilized BPC-157 is conventionally kept refrigerated at 2–8 °C and protected from light, with freezing used for long-term holding. The published stability work on this peptide concerns its unusual resistance to degradation in human gastric juice, not shelf life in a vial. No manufacturer stability data exists for unapproved material, so the handling conventions below come from general lyophilized-peptide practice rather than from any BPC-157 study.
Reconstituted storage
Once in solution, peptides are conventionally refrigerated at 2–8 °C, protected from light, and treated as short-dated rather than indefinitely stable. No published study establishes a solution shelf life for BPC-157.
Reconstitution diluent
The conventional diluent for lyophilized research peptides, including BPC-157, is bacteriostatic water: sterile water preserved with 0.9% benzyl alcohol. Sterile water without a preservative is used where a preservative is contraindicated, and is treated as single-use.
Reconstitution & handling
Conventional handling: sanitize the stopper before piercing it, add the diluent slowly down the inside wall of the vial rather than directly onto the powder, and let it dissolve on its own. Swirl gently if needed; never shake. A properly reconstituted solution is clear; anything cloudy, discolored, or carrying visible particulate is discarded. PHL does not publish volume or unit calculations, because those are dosing decisions and dosing decisions belong with a licensed clinician.
Handling notes
Because BPC-157 has no FDA-approved manufacturer, there is no label, no assigned beyond-use date, and no lot-level stability testing standing behind any particular storage claim. Treat all of the above as convention, not as a specification.

The how-to guides cover the conventions behind these fields, and what the published stability data does and does not establish: Storage, Reconstitution, Handling.

Goal pages that include BPC-157

Each one starts from the goal rather than the molecule, and grades what the evidence supports for that goal specifically.

  • Gut Healing

    A research reference for the peptides mapped to gut healing and intestinal repair. It covers what the rodent colitis literature established, why almost none of it has been tested in people, and what "healing the gut lining" does and does not mean in the published record.

  • Recovery

    A research reference for the peptides mapped to injury recovery and tissue repair, covering what the animal literature established, what the handful of human trials actually measured, and how to tell the two apart.

Questions for your provider

Bring this page to a licensed provider. A provider can order labs, review your medications and history, and tell you whether anything here is relevant to your situation. This page can't. Peptide Health Lab does not prescribe and does not sell peptides.

Want a structured starting point for that conversation? The Stack Builder turns your goals into a research-cited outline you can review together.

Citations

18 sources · every identifier checked against PubMed

Before you act on any of this

This page is educational only and is not medical advice. It does not diagnose, treat, or prescribe. Review it with a licensed provider before making any health decision. Peptide Health Lab does not sell peptides.

How we grade and verify evidence · Terms of Use · Privacy Policy

Open the Stack Builder